{
  "schema_version": "1.1",
  "disease": "esophageal cancer",
  "scope": {
    "subtype": "Esophageal adenocarcinoma (EAC)",
    "excludes": "ESCC (squamous) out of scope",
    "setting": "Full trajectory: Barrett's -> LGD/HGD -> intramucosal/early EAC -> locally advanced -> metastatic",
    "strategy_intent": "Strategies for any patient along the trajectory (interception through treatment)"
  },
  "created_at": "2026-07-11T16:52:45.274218+00:00",
  "updated_at": "2026-07-11T20:39:25.016170+00:00",
  "disease_archetype": "somatic",
  "mechanism_of_pathogenesis": "somatic_copy_number_and_TSG_loss",
  "causal_gene": null,
  "data_density": "rich",
  "modality": "engineered_antibody_binder (two arms)",
  "lead_targets": [
    {
      "target": "GUCY2C",
      "lane": "treatment",
      "druggability": "STRONG",
      "rank": 1,
      "rationale": "GI-epithelium luminal-restricted surface antigen; strong therapeutic window; antibody/ADC/bispecific/CAR viable; EAC whitespace"
    },
    {
      "target": "CDH17",
      "lane": "treatment",
      "druggability": "STRONG",
      "rank": 2,
      "rationale": "GI-restricted surface cadherin; emerging CAR/ADC target; low non-GI normal expression"
    },
    {
      "target": "CD276 (B7-H3)",
      "lane": "treatment",
      "druggability": "STRONG",
      "rank": 3,
      "rationale": "Surface antigen; ADC clinical-stage in EAC (ifinatamab deruxtecan); broader normal expression = window caution"
    },
    {
      "target": "CEACAM5",
      "lane": "treatment",
      "druggability": "STRONG",
      "rank": 4,
      "rationale": "GI-epithelial surface; ADC precedent; moderate window"
    },
    {
      "target": "DKK1",
      "lane": "progression",
      "druggability": "GOOD",
      "rank": 5,
      "rationale": "Secreted Wnt modulator; ligand-trap/neutralizing antibody; DKN-01 precedent; spans advanced + progression"
    }
  ],
  "patient_priorities": [
    "Preserve ability to eat/swallow (dysphagia is the defining burden)",
    "Survival WITH quality of life, not at any cost",
    "Minimize treatment toxicity/burden (favor targeted over cytotoxic)",
    "Reduce uncertainty (biomarkers, response signals, prognosis)",
    "Barrett's: less-invasive risk stratification + well-tolerated interception",
    "Dysplasia/early: organ preservation, durable clearance, avoid over/under-treatment",
    "Advanced: meaningful life extension with function + biomarker-guided access"
  ],
  "stages": {
    "1": {
      "name": "Indication & unmet need",
      "status": "complete",
      "confidence": "high",
      "skill_used": "drug-program-orchestration scope lock",
      "artifacts": [],
      "summary": "Scope locked: EAC subtype, full-trajectory strategy intent (Barrett's->metastatic).",
      "started_at": "2026-07-11T17:28:25.888391+00:00",
      "completed_at": "2026-07-11T20:28:40.693877+00:00"
    },
    "2": {
      "name": "Patient priorities / PFDD",
      "status": "complete",
      "confidence": "medium",
      "skill_used": "PFDD synthesis + people_first_language check",
      "artifacts": [
        {
          "filename": "patient_priorities_brief.md",
          "artifact_id": "657f4c53-f7a2-4953-9cfb-1791f12a640c",
          "version_id": "6f9a0145-a4b3-40c4-9c9c-600b24bf68b9"
        }
      ],
      "summary": "Patient priorities synthesized across trajectory: eating/swallowing, quality-of-life-weighted survival, low toxicity, reduced uncertainty, interception desire in Barrett's, organ preservation in dysplasia. Supports novelty-first + interception steer. Language check clean.",
      "completed_at": "2026-07-11T17:40:12.632271+00:00"
    },
    "3": {
      "name": "Literature + competitive-pipeline map",
      "status": "complete",
      "confidence": "high",
      "skill_used": "mcp-clinical-trials + mcp-drug-regulatory + Open Targets known drugs",
      "artifacts": [
        {
          "filename": "eac_whitespace_map.png",
          "artifact_id": "c7e47c80-8904-440b-866e-7f772ac49e68",
          "version_id": "62785261-5af5-4777-aad8-9e3d4f065560"
        },
        {
          "filename": "competitive_landscape.csv",
          "artifact_id": "1b8d216c-a452-42a7-b2b8-cfbc84ebd0e4",
          "version_id": "f26092ca-784e-4496-9636-ff9aeda16561"
        }
      ],
      "summary": "EAC landscape: 351 interventional trials (106 active), 203 Barrett's/dysplasia trials, 106 known drugs. CROWDED: PD-1/PD-L1 (41 mentions, approved incl. adjuvant), HER2 (12, T-DXd approved), VEGF (ramucirumab). RECENTLY VALIDATED: Claudin-18.2 (zolbetuximab 2024). EMERGING: FGFR2b, TIGIT. WHITESPACE (aligns with novelty steer): B7-H3, TROP2, GUCY2C surface-antigen ADCs; CD73; DKK1; and molecular Barrett's interception.",
      "completed_at": "2026-07-11T17:43:44.122215+00:00"
    },
    "4": {
      "name": "Data mining -> target nomination",
      "status": "complete",
      "confidence": "medium",
      "skill_used": "Open Targets tractability/association + cBioPortal genomics + curated druggability triage",
      "artifacts": [
        {
          "filename": "target_nomination.png",
          "artifact_id": "64fa8eed-3b56-49b9-a6b1-9f7c633b882d",
          "version_id": "612be213-674d-4bd9-94da-3f5e1ea003b9"
        },
        {
          "filename": "target_nomination.csv",
          "artifact_id": "c545b926-8603-481e-99ea-ea5e5ce1f267",
          "version_id": "6393a785-270f-4ee4-9e66-0d1a6b88a1ef"
        }
      ],
      "summary": "Ranked 16 candidates across treatment (surface antigens) and interception (progression) lanes. Honest druggability filter: raw-composite leaders GPX7 (lost TSG, not binder-addressable) and REG4/OLFM4/TFF3 (secreted biomarkers, unproven Rx) scored DOWN. True biologic-druggable + novel leads: GUCY2C, CDH17, CD276(B7-H3), CEACAM5 (surface, treatment) and DKK1 (secreted trap, progression). GUCY2C leads on therapeutic-window/GI-restriction.",
      "completed_at": "2026-07-11T17:49:50.972547+00:00"
    },
    "5": {
      "name": "Target & modality selection",
      "status": "complete",
      "confidence": "high",
      "skill_used": "recommend_modality router + biology triage + Open Targets Barrett's associations",
      "artifacts": [],
      "summary": "TWO-LEAD trajectory-spanning lock. TREATMENT: GUCY2C T-cell engager (bispecific) for advanced/peri-op EAC (luminal-restricted surface antigen, tumor polarity loss = window). INTERCEPTION: DKK1 neutralizing antibody/ligand-trap for Barrett's->dysplasia progression (secreted Wnt driver; DKN-01 precedent). Both converge on engineered protein binders -> one Stage-6 design pipeline run twice. Deliberately avoided a surface intestinal-metaplasia marker for the prevention arm (normal-gut selectivity risk).",
      "completed_at": "2026-07-11T17:54:12.631771+00:00"
    },
    "6": {
      "name": "Design & computational pressure-test",
      "status": "complete",
      "confidence": "medium",
      "skill_used": "RFdiffusion + ProteinMPNN + Boltz-2 (Modal A100 GPU)",
      "artifacts": [
        {
          "filename": "design_results.png",
          "artifact_id": "b9b46e8e-ab13-44ba-8309-e4bbb39504de",
          "version_id": "93c508bd-3c9a-4ce6-bb2c-9c11597abdff"
        },
        {
          "filename": "design_leads.csv",
          "artifact_id": "7a11d13b-c9ff-4f69-bb40-e27999a04e4a",
          "version_id": "383765ca-9d5d-45fb-894d-d116d69cfaa7"
        },
        {
          "filename": "gucy2c_bb2_complex.pdb",
          "artifact_id": "1a24719c-a39e-44fa-9ee0-f0e5b20b6292",
          "version_id": "e33914df-52df-4a9f-adc7-9eff47782562"
        },
        {
          "filename": "dkk1_bb1_complex.pdb",
          "artifact_id": "3773889d-51f9-403e-a3ac-bdf8b98bab9f",
          "version_id": "9e266b21-4d4a-4462-b3a2-a45f2de194ce"
        }
      ],
      "summary": "De novo binder campaign for BOTH arms. 8 backbones/target -> ProteinMPNN (binder chain) -> Boltz-2 fold-back. GUCY2C: 7/8 pass ipTM>0.5, top gucy2c_bb2 ipTM=0.915/pLDDT=0.896. DKK1: 8/8 pass, top dkk1_bb1 ipTM=0.858/pLDDT=0.908. Real computational design leads generated and validated in-silico. Caveats logged (single-model confidence, no wet-lab, GUCY2C arm needs bispecific formatting).",
      "completed_at": "2026-07-11T20:24:16.827965+00:00"
    },
    "7": {
      "name": "Scientific development plan",
      "status": "complete",
      "confidence": "high",
      "skill_used": "scientific_plan_template + dossier synthesis",
      "artifacts": [
        {
          "filename": "scientific_development_plan.md",
          "artifact_id": "9bb5b887-c583-40df-83ed-5287faba8c8a",
          "version_id": "86a1bf00-1954-4caa-ab9c-df7914e55316"
        }
      ],
      "summary": "Dual-arm scientific development plan: computational engine, in-vitro cascade, delivery, preclinical, CMC/IND, CDx, PD/biomarker gates (G1-G5), open questions (O-1..O-5). GUCY2C treatment + DKK1 interception.",
      "completed_at": "2026-07-11T20:25:48.609397+00:00"
    },
    "8": {
      "name": "Regulatory strategy",
      "status": "complete",
      "confidence": "medium",
      "skill_used": "Drugs@FDA precedents + ClinicalTrials.gov landscape synthesis",
      "artifacts": [
        {
          "filename": "regulatory_brief.md",
          "artifact_id": "5da38d52-a1a2-4c87-996a-d9fbdd26bbf8",
          "version_id": "3842f178-7e3d-4f10-95ea-a9f9c78af43a"
        }
      ],
      "summary": "Regulatory brief: treatment arm follows established EAC antibody/ADC/checkpoint precedent (accel approval ORR/PFS -> OS + CDx); interception arm faces no-precedent chemoprevention pathway (dysplasia-regression surrogate = central risk A-2/O-4). Assumptions A-1..A-4 flagged; two first FDA interactions recommended.",
      "completed_at": "2026-07-11T20:26:43.178034+00:00"
    },
    "9": {
      "name": "Commercial & financing",
      "status": "complete",
      "confidence": "medium",
      "skill_used": "epidemiology (SEER/CA Cancer J Clin, Barrett's prevalence) + FDA-comparable market synthesis",
      "artifacts": [
        {
          "filename": "commercial_financing_brief.md",
          "artifact_id": "933d6e50-2097-444d-adbb-448e85372244",
          "version_id": "fc823873-bf00-4f2c-8f22-5035be76f986"
        }
      ],
      "summary": "Commercial/financing brief. EAC ~22,370 US cases/yr (rising), Barrett's ~3M/up to 5.6% adults. Treatment arm = de-risked-by-precedent biomarker-selected biologic (gated on GI window); interception arm = first-in-class high-upside/high-uncertainty (gated on surrogate + payer). Staged milestone-gated financing, treatment-arm-first. Assumptions C-1..C-4 flagged.",
      "completed_at": "2026-07-11T20:27:39.980662+00:00"
    },
    "10": {
      "name": "Deliverables & synthesis",
      "status": "complete",
      "confidence": "high",
      "skill_used": "program_verdict + full-dossier synthesis",
      "artifacts": [
        {
          "filename": "FINAL_program_deliverable.md",
          "artifact_id": "79794123-a730-490d-aa2f-ca24562accfd",
          "version_id": "59de7c04-fee5-40c0-95e2-8a7a2469ce65"
        }
      ],
      "summary": "Final synthesized deliverable + verdict (TRACTABLE, 0.83). All 10 stages complete, all soft/hard gates through Stage 9 passed. FINAL REVIEW pending user sign-off.",
      "completed_at": "2026-07-11T20:28:54.498834+00:00"
    },
    "1b": {
      "name": "1b",
      "artifacts": [
        {
          "filename": "eac_driver_landscape.png",
          "artifact_id": "7907324b-ca31-48d1-9210-24869c271fc9",
          "version_id": "e15e8f35-f974-4874-966a-c7de9334a1ff"
        }
      ],
      "status": "complete",
      "started_at": "2026-07-11T17:34:19.168773+00:00",
      "skill_used": "classify_archetype/data_triage + cBioPortal + Open Targets",
      "summary": "EAC = somatic, chromosomally-unstable, copy-number-driven adenocarcinoma. Rich data. Metaplasia-dysplasia-carcinoma axis; amplified surface RTKs (HER2/EGFR) + angiogenic VEGFA are the drug-tractable drivers. STEER: novelty-first (avoid HER2/EGFR/VEGFA crowd).",
      "completed_at": "2026-07-11T17:35:00.862848+00:00",
      "confidence": "high"
    }
  },
  "gates": {
    "SCOPE LOCK": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "EAC subtype; full-trajectory setting confirmed by user.",
      "resolved_at": "2026-07-11T17:28:25.888420+00:00"
    },
    "ARCHETYPE LOCK": {
      "type": "hard",
      "status": "passed",
      "question": "Confirm EAC classified as somatic, copy-number-driven adenocarcinoma with metaplasia-dysplasia-carcinoma pathogenesis; rich data; target the amplified surface/secreted drivers.",
      "resolution": "User confirmed somatic/CN-driven EAC classification. STEER: prioritize NOVEL biology over known drivers (HER2/EGFR/VEGFA already drugged) -> steer target mining toward under-exploited amplicons, surfaceome, and immune targets.",
      "resolved_at": "2026-07-11T17:39:10.962766+00:00"
    },
    "PRIORITY RANK": {
      "type": "soft",
      "status": "passed",
      "question": null,
      "resolution": "Priorities recorded; soft gate. Interception + low-toxicity targeting reinforced as program values.",
      "resolved_at": "2026-07-11T17:40:12.632668+00:00"
    },
    "WHITESPACE CONFIRM": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "Confirmed whitespace: novel surface antigens (treatment) + molecular Barrett's interception. USER: mine BOTH lanes, evidence-rank into one trajectory-spanning table.",
      "resolved_at": "2026-07-11T17:44:57.479715+00:00"
    },
    "DATA SUFFICIENCY": {
      "type": "soft",
      "status": "passed",
      "question": null,
      "resolution": "Rich data (TCGA/cBioPortal cohorts, Open Targets, GEO available). Sufficient for omics-driven target nomination.",
      "resolved_at": "2026-07-11T17:44:57.479747+00:00"
    },
    "TARGET EVIDENCE": {
      "type": "soft",
      "status": "passed",
      "question": null,
      "resolution": "Evidence graded; secreted biomarkers & lost-TSG down-weighted honestly. 5 lead candidates carried to Stage 5.",
      "resolved_at": "2026-07-11T17:49:50.972830+00:00"
    },
    "TARGET/MODALITY LOCK": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "User confirmed: GUCY2C T-cell engager (treatment) + DKK1 neutralizing trap (interception).",
      "resolved_at": "2026-07-11T17:54:12.632043+00:00"
    },
    "DESIGN GO/NO-GO": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "Full GPU campaign run; 15/16 designs pass ipTM>0.5; leads for both arms validated in-silico.",
      "resolved_at": "2026-07-11T20:24:16.828037+00:00"
    },
    "REG ASSUMPTIONS": {
      "type": "soft",
      "status": "passed",
      "question": null,
      "resolution": "Regulatory assumptions surfaced explicitly (A-1..A-4); interception surrogate endpoint flagged as central uncertainty.",
      "resolved_at": "2026-07-11T20:26:43.178101+00:00"
    },
    "FINANCING ASSUMPTIONS": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "Market/financing assumptions surfaced (C-1..C-4); treatment-arm-first staging with milestone gates; interception as option value.",
      "resolved_at": "2026-07-11T20:27:39.980726+00:00"
    },
    "FINAL REVIEW": {
      "type": "hard",
      "status": "passed",
      "question": null,
      "resolution": "User accepted the dual-arm EAC program as delivered (verdict tractable, 0.83).",
      "resolved_at": "2026-07-11T20:30:48.959756+00:00"
    },
    "LOW CONFIDENCE": {
      "type": "soft",
      "status": "skipped",
      "question": null,
      "resolution": "Verdict tier=tractable (0.83); low-confidence path not triggered.",
      "resolved_at": "2026-07-11T20:28:54.498905+00:00"
    }
  },
  "decisions": [],
  "open_questions": [
    {
      "id": "O-1",
      "q": "ESM developability/liability screen + orthogonal fold-back (Chai-1/AF2) on leads",
      "status": "open",
      "kind": "computational"
    },
    {
      "id": "O-2",
      "q": "GUCY2C normal-gut therapeutic window (human IHC + TDCC selectivity; mouse cross-reactivity)",
      "status": "open",
      "kind": "preclinical"
    },
    {
      "id": "O-3",
      "q": "GUCY2C T-cell-engager GI toxicity manageable at efficacious dose",
      "status": "open",
      "kind": "clinical"
    },
    {
      "id": "O-4",
      "q": "DKK1 interception surrogate endpoint (dysplasia regression) acceptance + safety bar",
      "status": "open",
      "kind": "clinical/regulatory"
    },
    {
      "id": "O-5",
      "q": "Epitope hotspots validated as functional (LRP6-block for DKK1; tumor-exposed for GUCY2C)",
      "status": "open",
      "kind": "computational/experimental"
    }
  ],
  "deliverables": [],
  "archetype_detail": {
    "classification": "Somatic, chromosomally-unstable adenocarcinoma; NOT germline-monogenic",
    "pathogenesis_axis": "Barrett's metaplasia -> LGD/HGD -> intramucosal -> invasive EAC; driven by early TP53 loss + genome doubling, then focal amplifications (ERBB2, CCND1, MYC, GATA6, VEGFA, EGFR, CCNE1) and TSG deletions (CDKN2A, SMAD4)",
    "driver_frequencies_TCGA_EAC_n182": {
      "TP53_mut": 0.87,
      "CDKN2A_homdel": 0.39,
      "CCND1_amp": 0.35,
      "WWOX_del": 0.34,
      "MYC_amp": 0.22,
      "ERBB2_amp": 0.15,
      "VEGFA_amp": 0.12,
      "EGFR_amp": 0.12,
      "GATA6_amp": 0.11,
      "CCNE1_amp": 0.08,
      "SMAD4_homdel": 0.08
    },
    "implication": "Copy-number/amplification-driven -> favors targeting amplified cell-surface receptors (HER2, EGFR) and secreted/angiogenic factors (VEGFA); intracellular TSG loss (TP53/CDKN2A) is hard-to-drug and points to synthetic-lethal or interception strategies",
    "data_sources": [
      "cBioPortal esca_tcga_pan_can_atlas_2018 (n=182)",
      "Open Targets MONDO_0005028 (EAC, 3288 assoc targets); MONDO_0013662 (Barrett's, 2491)"
    ]
  },
  "program_steer": {
    "novelty_priority": true,
    "deprioritize_known_drugged": [
      "ERBB2/HER2",
      "EGFR",
      "VEGFA/VEGFR2",
      "CLDN18.2",
      "FGFR2b",
      "PD-1/PD-L1"
    ],
    "seek": [
      "under-exploited focal amplicons",
      "tumor surfaceome / novel cell-surface antigens",
      "immune/immuno-oncology targets",
      "interception (Barrett's->dysplasia) biology"
    ],
    "rationale": "Differentiated program requires whitespace; known drivers are crowded (Stage 3 will confirm)."
  },
  "landscape_counts": {
    "interventional_EAC_trials": 351,
    "active_EAC_trials": 106,
    "barretts_dysplasia_trials": 203,
    "ot_known_drugs": 106
  },
  "stage4_scope": {
    "lanes": [
      "novel_surface_antigens_treatment",
      "barretts_dysplasia_interception"
    ],
    "instruction": "one ranked table spanning trajectory; deprioritize HER2/EGFR/VEGFA/PD-1/CLDN18.2/FGFR2b"
  },
  "program_arms": {
    "treatment": {
      "target": "GUCY2C",
      "setting": "advanced / peri-operative EAC",
      "modality": "T-cell engager (anti-GUCY2C x anti-CD3 bispecific)",
      "design_task": "de novo/engineered anti-GUCY2C binder arm + CD3 arm; validate GUCY2C-arm interface",
      "window_rationale": "GI-luminal apical restriction; tumor loses polarity -> vascular accessibility",
      "risk": "on-target/off-tumor GI toxicity; CRS -> requires window/affinity engineering"
    },
    "interception": {
      "target": "DKK1",
      "setting": "Barrett's -> dysplasia -> early EAC (prevention)",
      "modality": "neutralizing antibody / ligand-trap",
      "design_task": "engineered DKK1-neutralizing binder (trap the secreted ligand)",
      "window_rationale": "secreted target; DKN-01 clinical precedent in esophagogastric",
      "risk": "long progression endpoints; Wnt-axis modulation safety"
    }
  },
  "design_leads": {
    "GUCY2C_treatment_arm": {
      "top_lead": "gucy2c_bb2",
      "binder_len": 71,
      "iptm": 0.915,
      "complex_plddt": 0.896,
      "n_designs": 8,
      "n_pass_iptm": 7,
      "note": "Binder arm for anti-GUCY2C x anti-CD3 T-cell engager; would be paired with a CD3 arm"
    },
    "DKK1_interception_arm": {
      "top_lead": "dkk1_bb1",
      "binder_len": 63,
      "iptm": 0.858,
      "complex_plddt": 0.908,
      "n_designs": 8,
      "n_pass_iptm": 8,
      "note": "Neutralizing binder against DKK1 CRD2 (LRP6-binding region); ligand-trap format"
    },
    "pipeline": "RFdiffusion (Complex_base_ckpt) -> ProteinMPNN (v_48_020, chain B) -> Boltz-2 fold-back (--use_msa_server, 5 diffusion samples)",
    "caveats": [
      "in-silico only; single-model Boltz confidence, no orthogonal (Chai-1/AF2) consensus yet",
      "GUCY2C binder is one arm of a bispecific; CD3 arm + format engineering not done",
      "no experimental validation; ipTM is a docking-confidence proxy not affinity",
      "epitope hotspots chosen by exposure/confidence heuristic, not by known functional site mapping"
    ]
  },
  "verdict": {
    "tier": "tractable",
    "score": 0.87,
    "rationale": "score=0.87 (mean stage confidence=0.82; target_evidence_gate=passed; design_gate=passed; data_density=rich; open_questions=5).",
    "best_next_step": "Advance the lead(s) into the scientific development plan; the evidence supports a fundable program.",
    "requires_human_confirmation": true
  },
  "program_status": "complete"
}